China’ Simcere To Sell Its 35% Stake In Shanghai Celgen
This article was originally published in PharmAsia News
Executive Summary
China’sSimcere Pharmaceutical Group plans to sell its 35% stake in Shanghai Celgen Bio-Pharmaceutical Co. Ltd. for $48 million, exiting a deal signed in 2009.